Long-Term Follow-Up Defines the Population That Benefits from Early Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial Using the Combination of Ixazomib, Lenalidomide, and Dexamethasone
长期随访确定了在一项使用伊沙佐米、来那度胺和地塞米松联合治疗的高风险冒烟型多发性骨髓瘤临床试验中受益于早期拦截的人群
期刊:
影响因子:
doi:10.1101/2024.04.19.24306082
Omar Nadeem, Michelle P Aranha, Robert Redd, Michael Timonian, Sophie Magidson, Elizabeth D Lightbody, Jean-Baptiste Alberge, Luca Bertamini, Ankit K Dutta, Habib El-Khoury, Mark Bustoros, Jacob P Laubach, Giada Bianchi, Elizabeth O'Donnell, Ting Wu, Junko Tsuji, Kenneth Anderson, Gad Getz, Lorenzo
